蛭龙胶囊联合坎地沙坦对早期糖尿病肾病大鼠纤溶系统的影响

摘要

目的:探讨蛭龙胶囊联合坎地沙坦对早期糖尿病肾病(DN)大鼠纤溶系统的影响.方法:采用高糖高脂饲料联合腹腔注射STZ的方法制备DN模型,分力以不同药物对模型鼠进行灌胃,采用酶联免疫法测定各组大鼠血浆tPA、PAI水平,观察肾脏病理形态学的变化.结果:各治疗组均能显著下调PAI(正常组19.58±3.12,模型组42.10±6.40,蛭龙胶囊组33.24±7.08,坎地沙坦组32.41±4.15,联合用药组28.08±4.94)含量及PAI/tPA值,上调tPA(正常组12.78±2.80,模型组6.32±1.46,蛭龙胶囊组7.63±1.85,坎地沙坦组7.87±1.66,联合用药组9.61±1.77)含量(P＜0.01,P＜0.05),减轻肾小球及肾小管损害,以联合用药组为著.结论:蛭龙胶囊联合坎地沙坦可以调节tPA与PAI的平衡,促进细胞外基质降解而延缓早期DN的进展.%Objective:To investigate the effection of Zhilong capsule combined with candesartan on early diabetic nephropathy of rats in fibrinolytic system.Methods:Establish the early stage DN model by high sucrose,fat diet and intraperitoneal injection of STZ.Treated with Zhilong capsule and candesartan recipe for 8 weeks,measured the level of tPA、PAI serum by radioimmunoassay,and observed the impaction of renal pathological morphology by optical microscopy.Results:All the groups of treatment can reduce the level of PAI (normal control group 19.58 ± 3.12,model control group 42.10 ± 6.40,Zhilong capsule treatment group 33.24 ± 7.08,candesartan cilexetil treatment group 32.41 ± 4.15,combined treatment group 28.08 ± 4.94) content and PAI/tPA value,increase tPA (normal control group 12.78 ± 2.80,model control group 6.32 ± 1.46,Zhilong capsule treatment group 7.63 ± 1.85,candesartan cilexetil treatment group 7.87 ± 1.66,combined treatment group 9.61 ± 1.77) content(P ＜ 0.01,P ＜ 0.05),and relieve the damage of glomerular and renal tubular in the diabetic nephropathy rats,and the result of Zhilong capsule combined with candesartan group is the most significantly.Conclusion:Zhilong capsule combined with candesartan can regulated the balance of tPA and PAI,promote the degradation of extracellular matrix and retard the progression of diabetic nephropathy in early stage.